Civica Rx, in collaboration with Biocon Biologics, is also working to develop additional interchangeable biosimilar insulins

California will begin selling CalRx insulin glargine pens to consumers starting Jan. 1, 2026, at a suggested retail price of no more than $55 for a five-pack, equating to an average of $11 per pen. The announcement came with the insulin, an interchangeable biosimilar to Lantus, set to be available through an agreement between nonprofit generic drug manufacturer Civica Rx and Biocon Biologics.

The state’s pharmacies will purchase the 3 mL pens for $45 per five-pack, a significant drop from current market prices, according to officials. Insulin glargine, a long-acting insulin analog, is widely used to manage diabetes. The move follows California’s initiative to produ

See Full Page